Clinical trial
A Phase I and Pharmacokinetic Study of NM-3 Administered Orally Once or Twice Daily on Five Consecutive Days and Repeated Weekly for Six Weeks Every Eight Weeks in Patients With Advanced Solid Tumors.
NCT00046696 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I and Pharmacokinetic Study of NM-3 Administered Orally Once or Twice Daily on Five Consecutive Days and Repeated Weekly for Six Weeks Every Eight Weeks in Patients With Advanced Solid Tumors.
- Lead sponsor
- Genzyme, a Sanofi Company
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 31, 2001
- Completion date
- October 31, 2006
- Enrollment
- 32
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.